In diabetes and heart failure, SGLT2 blockade improves renal prognosis by reducing hypoxia, inflammation, and oxidative stress in the tubulointerstitium and suppressing renal sympathetic nervous system activity; the latter effect decreases renal reabsorption of Na+ and water and dilates the capacitance vessels, thus reducing the preload to the heart [23,24,25,26]. This evidence concerns the gene SLC5A2 and diabetes mellitus.